BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17668794)

  • 1. [More and more discount contracts. A chance to be free of the budget pressure].
    Schmidt K
    MMW Fortschr Med; 2007 May; 149(19):54-5. PubMed ID: 17668794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 3. [Scope of the contract for drug therapy. Rebate contracts also for original drugs].
    MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
    Göddertz R
    MMW Fortschr Med; 2013 Apr; 155(7):16. PubMed ID: 23668163
    [No Abstract]   [Full Text] [Related]  

  • 5. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug costs in Germany: 12 poorer countries are the benchmark].
    Laschet H
    MMW Fortschr Med; 2012 Nov; 154(21):12. PubMed ID: 23270047
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discount contracts between industry and public health insurance. Analog insulin preparations still reimbursable].
    Schmidt K
    MMW Fortschr Med; 2006 Nov; 148(48):60. PubMed ID: 17615776
    [No Abstract]   [Full Text] [Related]  

  • 9. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 10. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 11. [More than "cheap copies". Generic drugs promote medical progress].
    MMW Fortschr Med; 2004 Jun; 146(24):51. PubMed ID: 15366498
    [No Abstract]   [Full Text] [Related]  

  • 12. [Generic drugs--medical progress at a moderate price].
    Müller M
    Wien Klin Wochenschr; 2003 Jan; 115(1-2):1-2. PubMed ID: 12658903
    [No Abstract]   [Full Text] [Related]  

  • 13. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 14. [Price of medications: the actual system must be seen again].
    Mayencourt J
    Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on "Where's the value in health care"?
    Lungen M; Gerber A
    Value Health; 2007; 10(2):170; author reply 171. PubMed ID: 17391426
    [No Abstract]   [Full Text] [Related]  

  • 16. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 17. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity].
    Puig-Junoy J
    Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178
    [No Abstract]   [Full Text] [Related]  

  • 18. Australian drugs scheme threatens free-trade talks.
    Fickling D
    Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
    [No Abstract]   [Full Text] [Related]  

  • 19. [Due to cost considerations too few triptans are prescribed].
    Diener HC
    MMW Fortschr Med; 2006 Apr; 148(16):63. PubMed ID: 16688955
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cost reducing of or by drugs. More rationality and efficiency in drug therapy].
    Glaeske G
    Internist (Berl); 2010 Aug; 51(8):1057-60, 1062-3. PubMed ID: 20552155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.